Cargando…

Effects of Exenatide Alone and in Combination With Daclizumab on β-Cell Function in Long-Standing Type 1 Diabetes

OBJECTIVE: In patients with long-standing type 1 diabetes, we investigated whether improved β-cell function can be achieved by combining intensive insulin therapy with agents that may 1) promote β-cell growth and/or limit β-cell apoptosis and 2) weaken the anti–β-cell autoimmunity. RESEARCH DESIGN A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rother, Kristina I., Spain, Lisa M., Wesley, Robert A., Digon, Benigno J., Baron, Alain, Chen, Kim, Nelson, Patric, Dosch, H.-Michael, Palmer, Jerry P., Brooks-Worrell, Barbara, Ring, Michael, Harlan, David M.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782986/ https://www.ncbi.nlm.nih.gov/pubmed/19808924 http://dx.doi.org/10.2337/dc09-0773

Ejemplares similares

Exenatide Improves HDL Particle Counts and Size Distribution in Patients With Long-standing Type 1 Diabetes
por: Gourgari, Evgenia A., et al.
Publicado: (2017)

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
por: Sarkar, Gayatri, et al.
Publicado: (2014)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

Response to Comment on Sarkar et al. Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Diabetes Care 2014;37:666–670
por: Sarkar, Gayatri, et al.
Publicado: (2014)

Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes
por: Herold, Kevan C., et al.
Publicado: (2009)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
por: Karunaratne, Kushan, et al.
Publicado: (2021)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
por: Mullen, John C, et al.
Publicado: (2014)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
por: Gold, Ralf, et al.
Publicado: (2016)

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS
por: Luessi, Felix, et al.
Publicado: (2018)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients
por: Rommer, Paulus S., et al.
Publicado: (2020)

Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry
por: Ranganath, Thanmayi, et al.
Publicado: (2020)

Audit for Stand Alone Systems
por: Ferguson, J
Publicado: (1986)

Oxytocin does not stand alone
por: Putnam, Philip T., et al.
Publicado: (2022)

Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes
por: Ionut, Viorica, et al.
Publicado: (2016)

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
por: Lin, Yen Chih, et al.
Publicado: (2016)

DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?
por: Avasarala, Jagannadha
Publicado: (2018)

Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease
por: Rager, Alison, et al.
Publicado: (2010)

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Sageshima, Junichiro, et al.
Publicado: (2009)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
Publicado: (2021)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

The use of exenatide in severely burned pediatric patients
por: Mecott, Gabriel A, et al.
Publicado: (2010)

Automated Design of Diverse Stand-Alone Riboswitches
por: Wu, Michelle J., et al.
Publicado: (2019)

Stand-Alone GNSS Sensors as Velocity Seismometers: Real-Time Monitoring and Earthquake Detection
por: Hohensinn, Roland, et al.
Publicado: (2018)

Impact of Islet Autoimmunity on the Progressive β-Cell Functional Decline in Type 2 Diabetes
por: Brooks-Worrell, Barbara M., et al.
Publicado: (2014)

Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis
por: Hu, Yan, et al.
Publicado: (2023)

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
por: Liu, Que, et al.
Publicado: (2010)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation
por: Saghafi, Hossein, et al.
Publicado: (2012)

Comment on: Keenan et al. (2010) Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study. Diabetes 2010;59:2846–2853
por: Rother, Kristina I., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vm9s6jj4gtvqc4b4dpa844g9nc